TABLE I.
Arthralgia rates in major clinical trials of aromatase inhibitors
| Reference (trial name) | Follow-up (months) | Rate of arthralgia (%) with | p Value | Comments | |||
|---|---|---|---|---|---|---|---|
| Tamoxifen | Anastrozole | Letrozole | Exemestane | ||||
| Coombes et al., 2004 4 (ies 30) | 6 | 3.6 | 5.4 | 0.01 | Women were switched to exemestane after 2–3 years of tamoxifen | ||
| Goss et al., 2005 5 (ma.17) | 30 | 21 | 25 | 0.001 | Women were switched to letrozole after 5 years of tamoxifen More women experienced myalgia than experienced arthritis |
||
| Howell et al., 2005 6 (atac) | 60 | 29.4 | 35.6 | 0.0001 | |||
| Coates et al., 2007 7 (big 1–98) | 51 | 13.5 | 20 | <0.001 | |||
ies = International Exemestane Study; atac = Arimidex, Tamoxifen, Alone or in Combination; big = Breast International Group.